HCV versus HIV drug discovery: Déjà vu all over again?

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2281-7. doi: 10.1016/j.bmcl.2013.02.070. Epub 2013 Feb 26.

Abstract

Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral replication with once-daily regimens. More recent research into HCV therapeutics have also resulted in very promising clinical candidates. This Digest explores similarities and differences in the two fields and compares the chronology of drug discovery relative to the availability of enabling tools, and concludes that safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than was the case for HIV.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents / therapeutic use*
  • Drug Discovery / methods
  • HIV / physiology
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Hepacivirus / physiology
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Humans
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents
  • Antiviral Agents